National Cancer Institute; Notice of Closed Meeting, 51838 [06-7336]

Download as PDF 51838 Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices erjones on PROD1PC72 with NOTICES responses in patients with autoimmune diseases; (3) Development of vaccines candidates for cancer and infectious diseases; (4) Organ transplant diagnostics and immunotherapeutics. Inventors: William Biddison, Richard Turner, Susan Gagnon (NINDS). Relevant Publications: 1. TK Baxter, SJ Gagnon, RL DavisHarrison, JC Beck, AK Binz, RV Turner, WE Biddison. Strategic mutations in the class I major histocompatibility complex HLA–A2 independently affect both peptide binding and T cell receptor recognition. J. Biol. Chem. 2004 Jul 9; 279(28):29175–29184. 2. BM Baker, RV Turner, SJ Gagnon, DC Wiley, WE Biddison. Identification of a crucial energetic footprint on the alpha1 helix of human histocompatibility leukocyte antigen (HLA)–A2 that provides functional interactions for recognition by tax peptide/HLA–A2-specific T cell receptors. J. Exp. Med. 2001 Mar 5; 193(5):551–562. Patent Status: HHS Reference Nos. E– 251–2006/0 and E–251–2006/1— Biological Materials. Licensing Status: Available for licensing through Biological Materials License Agreements. Licensing Contact: Susan Ano, Ph.D.; 301/435–5515; anos@mail.nih.gov. Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin A Description of Technology: Available for licensing from the NIH are two chimpanzee-derived monoclonal antibodies (mAbs) against botulinum neurotoxin type A (BoNT/A). These mAbs can be developed for prevention, therapy, or diagnosis of BoNT/A. Use of this technology represents a significant improvement over the existing therapy of supportive care and treatment with equine antitoxin polyclonal antibodies. Potential Applications of Technology: (1) Emergency prophylaxis against BoNT/A outbreak (natural or biodefense-related); (2) Therapeutic against BoNT/A; (3) Rapid Diagnosis of BoNT/A; (4) Therapeutic against overdosage of BoNT/A as used in clinical treatments. Advantages of Existing Therapies: (1) No anticipated side effects compared to currently utilized equine antitoxin polyclonal antibodies; (2) Monoclonal instead of polyclonal. Inventors: Robert H. Purcell et al. (NIAID). Patent Status: HHS Reference No. E– 180–2006/0—Research Tool. Licensing Status: Available for nonexclusive licensing. Licensing Contact: Susan Ano, Ph.D.; 301/435–5515; anos@mail.nih.gov. VerDate Aug<31>2005 15:29 Aug 30, 2006 Jkt 208001 Dated: August 25, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 06–7331 Filed 8–30–06; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Initial Review Group, Subcommittee F—Manpower & Training, NCI F—Initial Review of K01 and T32 Applications. Date: September 26–27, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007. Contact Person: Lynn M. Amende, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8105, Bethesda MD 20892, 301–451–4759, amendel@mail.nih.go. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 25, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–7336 Filed 8–30–06; 8:45 am] BILLING CODE 4140–01–M PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel, R03 Chemosense Scientific Review Panel. Date: October 5, 2006. Time: 11 a.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6120 Executive Blvd., Rockville, MD 20852, (Telephone Conference Call). Contact Person: Sheo Singh, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Activities, Executive Plaza South, Room 400C, 6120 Executive Blvd., Bethesda, MD 20892; 301–496–8683; singhs@nidcd.nih.gov. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel, R03 Voice and Language Scientific Review Meeting. Date: October 5, 2006. Time: 1 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6120 Executive Blvd., Rockville, MD 20852, (Telephone Conference Call). Contact Person: Shiguang Yang, PhD, DVM, Scientific Review Administrator, Division of Extramural Activities, NIDCD, NIH, 6120 Executive Blvd., Bethesda, MD 20892; 301–496–8683. Name of Committee: National Institute on Deafness and Other Communication Disorders Special Emphasis Panel, R03 Hearing and Balance Scientific Review Meeting. Date: October 6, 2006. Time: 11 a.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6120 Executive Blvd., Rockville, MD 20852, (Telephone Conference Call). Contact Person: Shiguang Yang, PhD, DVM, Scientific Review Administrator, E:\FR\FM\31AUN1.SGM 31AUN1

Agencies

[Federal Register Volume 71, Number 169 (Thursday, August 31, 2006)]
[Notices]
[Page 51838]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-7336]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Initial Review 
Group, Subcommittee F--Manpower & Training, NCI F--Initial Review of 
K01 and T32 Applications.
    Date: September 26-27, 2006.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., 
Washington, DC 20007.
    Contact Person: Lynn M. Amende, PhD, Scientific Review 
Administrator, Resources and Training Review Branch, Division of 
Extramural Activities, National Cancer Institute, 6116 Executive 
Blvd., Room 8105, Bethesda MD 20892, 301-451-4759, 
amendel@mail.nih.go.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: August 25, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-7336 Filed 8-30-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.